Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular engineering to improve antibodies' anti-lymphoma activity.

Best practice & research. Clinical haematology - 1 Jun 2011

Peipp Matthias, van de Winkel Jan G J, Valerius Thomas

Abstract excerpt

The human/mouse chimeric CD20 antibody rituximab has significantly improved the survival of lymphoma patients. However, translational research into pharmacology and effector mechanisms of rituximab has identified several limitations of this prototypic antibody. For example, humanized or fully human next-generation antibodies demonstrated reduced immunogenicity, which may translate into improved applicability in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Murine-Derived
Share to Antigens, CD20

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunity, Humoral

Share to Immunoglobulin Fc Fragments

Share to Immunoglobulin Isotypes

Share to Lymphoma, Follicular

Share to Primates

Share to Rituximab

Source

Identifiers

PMID: 21658620
DOI: 10.1016/j.beha.2011.03.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular engineering to improve antibodies' anti-lymphoma activity.PMID 21658620Read ↗

Antibody Structure and Function: The Basis for Engineering TherapeuticsSemantic proximity Read ↗

Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges.Semantic proximity Read ↗

Monoclonal antibodies: From magic bullet to precision weaponSemantic proximity Read ↗

Optimizing therapeutic antibody function: progress with Fc domain engineering.Semantic proximity Read ↗

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.Semantic proximity Read ↗

Antibody Engineering at the MillenniumSemantic proximity Read ↗

Antibody therapeutics:Semantic proximity Read ↗

Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-LifeSemantic proximity Read ↗

Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design.Semantic proximity Read ↗

Beyond antibodies: using biological principles to guide the development of next-generation protein therapeuticsSemantic proximity Read ↗

Mechanism of Action and Pharmacokinetics of Approved Bispecific AntibodiesSemantic proximity Read ↗

A computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of actionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.